Loading…

Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion

Background Use of cross matching or HLA matching for donor selection is the basis of managing patients refractory to platelet (PLT) transfusion. Because of changes in patient care, we evaluated the effect of cross matching and HLA matching in patients refractory to PLT transfusion. Study Design and...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion (Philadelphia, Pa.) Pa.), 2014-12, Vol.54 (12), p.3080-3087
Main Authors: Rioux-Massé, Benjamin, Cohn, Claudia, Lindgren, Bruce, Pulkrabek, Shelly, McCullough, Jeffrey
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5579-9e9deb986dea7449455fe4553d2dd16c287ab9c733e5f169d6dab0057a1b20d13
cites cdi_FETCH-LOGICAL-c5579-9e9deb986dea7449455fe4553d2dd16c287ab9c733e5f169d6dab0057a1b20d13
container_end_page 3087
container_issue 12
container_start_page 3080
container_title Transfusion (Philadelphia, Pa.)
container_volume 54
creator Rioux-Massé, Benjamin
Cohn, Claudia
Lindgren, Bruce
Pulkrabek, Shelly
McCullough, Jeffrey
description Background Use of cross matching or HLA matching for donor selection is the basis of managing patients refractory to platelet (PLT) transfusion. Because of changes in patient care, we evaluated the effect of cross matching and HLA matching in patients refractory to PLT transfusion. Study Design and Methods We identified all patients who received either HLA‐matched or cross‐matched PLTs during a 3‐year period at our medical center. Patient records were reviewed and laboratory data were collected. One‐ to 4‐hour corrected count increments (CCIs) were calculated for transfusions given up to 72 hours before receiving these specialized units and the HLA‐matched or cross‐matched units themselves. Results Thirty‐two patients were identified who received a total of 354 PLT transfusions. Of these, 161 were from unselected apheresis, 152 were cross matched, and 41 were HLA selected. The median CCI for random‐donor transfusions was 0 (range, 0 × 109‐10.5 × 109/L), for cross‐matched PLT transfusions 1.7 × 109/L (0 × 109‐5.1 × 109/L), and for HLA‐matched transfusions 1.2 × 109/L (0 × 109‐13.9 × 109/L). Only 25 and 30% of cross‐match–compatible or HLA‐selected units, respectively, gave 1‐ to 4‐hour CCIs of more than 5.0 × 109/L compared to 12% of the transfusions from random donors. There were no significant differences in the 1‐ to 4‐hour CCIs when comparing random units with HLA‐selected or cross‐match–compatible units. There was also no significant difference when comparing the HLA‐matched and cross‐match–compatible PLT units with each other. Conclusions The use of cross‐match–compatible or HLA‐matched units did not provide better increments in PLT count when compared to random nonselected units. Clinical factors may overpower immunologic matching.
doi_str_mv 10.1111/trf.12739
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1637567714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1637567714</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5579-9e9deb986dea7449455fe4553d2dd16c287ab9c733e5f169d6dab0057a1b20d13</originalsourceid><addsrcrecordid>eNp1kF9rFDEUxUNR2rX2oV-gDIigD9Pmz2SyeVyq24qLFmnpY8gkd-jU2cmaZND103u3u11BMA8Jl_zOufceQk4ZPWd4LnJszxlXQh-QCZNClVxr-YJMKK1YyZjgR-RVSo-UUq4pOyRHvNKsFlM-IXCXu777bXMXhiK0hYshpXJps3sAX4RYXC9m-3LV2ww95FS0-LNCEQxYRGijdTnEdZHDHipytENqx4TOr8nL1vYJTnbvMbmbf7y9vC4XX68-Xc4WpZNS6VKD9tDoae3BqqrSlZQt4CU8957Vjk-VbbRTQoBsWa197W1DqVSWNZx6Jo7Ju63vKoYfI6Rsll1y0Pd2gDAmg0srWSvFKkTf_IM-hjEOON2GklQJrjbU-y31lAsualaxW9q4NoyaTfYGszdP2SN7tnMcmyX4PfkcNgJvd4BNzvYY2uC69JfTdIqdBXIXW-5n18P6_x3N7bf5c-tyq-hShl97hY3fTa1wZXP_5crMP1Q3N_wzN_fiDyGhqlM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1635073274</pqid></control><display><type>article</type><title>Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Rioux-Massé, Benjamin ; Cohn, Claudia ; Lindgren, Bruce ; Pulkrabek, Shelly ; McCullough, Jeffrey</creator><creatorcontrib>Rioux-Massé, Benjamin ; Cohn, Claudia ; Lindgren, Bruce ; Pulkrabek, Shelly ; McCullough, Jeffrey</creatorcontrib><description>Background Use of cross matching or HLA matching for donor selection is the basis of managing patients refractory to platelet (PLT) transfusion. Because of changes in patient care, we evaluated the effect of cross matching and HLA matching in patients refractory to PLT transfusion. Study Design and Methods We identified all patients who received either HLA‐matched or cross‐matched PLTs during a 3‐year period at our medical center. Patient records were reviewed and laboratory data were collected. One‐ to 4‐hour corrected count increments (CCIs) were calculated for transfusions given up to 72 hours before receiving these specialized units and the HLA‐matched or cross‐matched units themselves. Results Thirty‐two patients were identified who received a total of 354 PLT transfusions. Of these, 161 were from unselected apheresis, 152 were cross matched, and 41 were HLA selected. The median CCI for random‐donor transfusions was 0 (range, 0 × 109‐10.5 × 109/L), for cross‐matched PLT transfusions 1.7 × 109/L (0 × 109‐5.1 × 109/L), and for HLA‐matched transfusions 1.2 × 109/L (0 × 109‐13.9 × 109/L). Only 25 and 30% of cross‐match–compatible or HLA‐selected units, respectively, gave 1‐ to 4‐hour CCIs of more than 5.0 × 109/L compared to 12% of the transfusions from random donors. There were no significant differences in the 1‐ to 4‐hour CCIs when comparing random units with HLA‐selected or cross‐match–compatible units. There was also no significant difference when comparing the HLA‐matched and cross‐match–compatible PLT units with each other. Conclusions The use of cross‐match–compatible or HLA‐matched units did not provide better increments in PLT count when compared to random nonselected units. Clinical factors may overpower immunologic matching.</description><identifier>ISSN: 0041-1132</identifier><identifier>EISSN: 1537-2995</identifier><identifier>DOI: 10.1111/trf.12739</identifier><identifier>PMID: 24916382</identifier><identifier>CODEN: TRANAT</identifier><language>eng</language><publisher>Hoboken, NJ: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Blood Platelets ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Child ; Female ; Histocompatibility Testing ; Humans ; Male ; Medical sciences ; Middle Aged ; Platelet Transfusion ; Retrospective Studies ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>Transfusion (Philadelphia, Pa.), 2014-12, Vol.54 (12), p.3080-3087</ispartof><rights>2014 AABB</rights><rights>2015 INIST-CNRS</rights><rights>2014 AABB.</rights><rights>Copyright © 2014 AABB</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5579-9e9deb986dea7449455fe4553d2dd16c287ab9c733e5f169d6dab0057a1b20d13</citedby><cites>FETCH-LOGICAL-c5579-9e9deb986dea7449455fe4553d2dd16c287ab9c733e5f169d6dab0057a1b20d13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=29086353$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24916382$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rioux-Massé, Benjamin</creatorcontrib><creatorcontrib>Cohn, Claudia</creatorcontrib><creatorcontrib>Lindgren, Bruce</creatorcontrib><creatorcontrib>Pulkrabek, Shelly</creatorcontrib><creatorcontrib>McCullough, Jeffrey</creatorcontrib><title>Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion</title><title>Transfusion (Philadelphia, Pa.)</title><addtitle>Transfusion</addtitle><description>Background Use of cross matching or HLA matching for donor selection is the basis of managing patients refractory to platelet (PLT) transfusion. Because of changes in patient care, we evaluated the effect of cross matching and HLA matching in patients refractory to PLT transfusion. Study Design and Methods We identified all patients who received either HLA‐matched or cross‐matched PLTs during a 3‐year period at our medical center. Patient records were reviewed and laboratory data were collected. One‐ to 4‐hour corrected count increments (CCIs) were calculated for transfusions given up to 72 hours before receiving these specialized units and the HLA‐matched or cross‐matched units themselves. Results Thirty‐two patients were identified who received a total of 354 PLT transfusions. Of these, 161 were from unselected apheresis, 152 were cross matched, and 41 were HLA selected. The median CCI for random‐donor transfusions was 0 (range, 0 × 109‐10.5 × 109/L), for cross‐matched PLT transfusions 1.7 × 109/L (0 × 109‐5.1 × 109/L), and for HLA‐matched transfusions 1.2 × 109/L (0 × 109‐13.9 × 109/L). Only 25 and 30% of cross‐match–compatible or HLA‐selected units, respectively, gave 1‐ to 4‐hour CCIs of more than 5.0 × 109/L compared to 12% of the transfusions from random donors. There were no significant differences in the 1‐ to 4‐hour CCIs when comparing random units with HLA‐selected or cross‐match–compatible units. There was also no significant difference when comparing the HLA‐matched and cross‐match–compatible PLT units with each other. Conclusions The use of cross‐match–compatible or HLA‐matched units did not provide better increments in PLT count when compared to random nonselected units. Clinical factors may overpower immunologic matching.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Blood Platelets</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Child</subject><subject>Female</subject><subject>Histocompatibility Testing</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Platelet Transfusion</subject><subject>Retrospective Studies</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0041-1132</issn><issn>1537-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp1kF9rFDEUxUNR2rX2oV-gDIigD9Pmz2SyeVyq24qLFmnpY8gkd-jU2cmaZND103u3u11BMA8Jl_zOufceQk4ZPWd4LnJszxlXQh-QCZNClVxr-YJMKK1YyZjgR-RVSo-UUq4pOyRHvNKsFlM-IXCXu777bXMXhiK0hYshpXJps3sAX4RYXC9m-3LV2ww95FS0-LNCEQxYRGijdTnEdZHDHipytENqx4TOr8nL1vYJTnbvMbmbf7y9vC4XX68-Xc4WpZNS6VKD9tDoae3BqqrSlZQt4CU8957Vjk-VbbRTQoBsWa197W1DqVSWNZx6Jo7Ju63vKoYfI6Rsll1y0Pd2gDAmg0srWSvFKkTf_IM-hjEOON2GklQJrjbU-y31lAsualaxW9q4NoyaTfYGszdP2SN7tnMcmyX4PfkcNgJvd4BNzvYY2uC69JfTdIqdBXIXW-5n18P6_x3N7bf5c-tyq-hShl97hY3fTa1wZXP_5crMP1Q3N_wzN_fiDyGhqlM</recordid><startdate>201412</startdate><enddate>201412</enddate><creator>Rioux-Massé, Benjamin</creator><creator>Cohn, Claudia</creator><creator>Lindgren, Bruce</creator><creator>Pulkrabek, Shelly</creator><creator>McCullough, Jeffrey</creator><general>Blackwell Publishing Ltd</general><general>Wiley</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201412</creationdate><title>Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion</title><author>Rioux-Massé, Benjamin ; Cohn, Claudia ; Lindgren, Bruce ; Pulkrabek, Shelly ; McCullough, Jeffrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5579-9e9deb986dea7449455fe4553d2dd16c287ab9c733e5f169d6dab0057a1b20d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Blood Platelets</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Child</topic><topic>Female</topic><topic>Histocompatibility Testing</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Platelet Transfusion</topic><topic>Retrospective Studies</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rioux-Massé, Benjamin</creatorcontrib><creatorcontrib>Cohn, Claudia</creatorcontrib><creatorcontrib>Lindgren, Bruce</creatorcontrib><creatorcontrib>Pulkrabek, Shelly</creatorcontrib><creatorcontrib>McCullough, Jeffrey</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rioux-Massé, Benjamin</au><au>Cohn, Claudia</au><au>Lindgren, Bruce</au><au>Pulkrabek, Shelly</au><au>McCullough, Jeffrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion</atitle><jtitle>Transfusion (Philadelphia, Pa.)</jtitle><addtitle>Transfusion</addtitle><date>2014-12</date><risdate>2014</risdate><volume>54</volume><issue>12</issue><spage>3080</spage><epage>3087</epage><pages>3080-3087</pages><issn>0041-1132</issn><eissn>1537-2995</eissn><coden>TRANAT</coden><abstract>Background Use of cross matching or HLA matching for donor selection is the basis of managing patients refractory to platelet (PLT) transfusion. Because of changes in patient care, we evaluated the effect of cross matching and HLA matching in patients refractory to PLT transfusion. Study Design and Methods We identified all patients who received either HLA‐matched or cross‐matched PLTs during a 3‐year period at our medical center. Patient records were reviewed and laboratory data were collected. One‐ to 4‐hour corrected count increments (CCIs) were calculated for transfusions given up to 72 hours before receiving these specialized units and the HLA‐matched or cross‐matched units themselves. Results Thirty‐two patients were identified who received a total of 354 PLT transfusions. Of these, 161 were from unselected apheresis, 152 were cross matched, and 41 were HLA selected. The median CCI for random‐donor transfusions was 0 (range, 0 × 109‐10.5 × 109/L), for cross‐matched PLT transfusions 1.7 × 109/L (0 × 109‐5.1 × 109/L), and for HLA‐matched transfusions 1.2 × 109/L (0 × 109‐13.9 × 109/L). Only 25 and 30% of cross‐match–compatible or HLA‐selected units, respectively, gave 1‐ to 4‐hour CCIs of more than 5.0 × 109/L compared to 12% of the transfusions from random donors. There were no significant differences in the 1‐ to 4‐hour CCIs when comparing random units with HLA‐selected or cross‐match–compatible units. There was also no significant difference when comparing the HLA‐matched and cross‐match–compatible PLT units with each other. Conclusions The use of cross‐match–compatible or HLA‐matched units did not provide better increments in PLT count when compared to random nonselected units. Clinical factors may overpower immunologic matching.</abstract><cop>Hoboken, NJ</cop><pub>Blackwell Publishing Ltd</pub><pmid>24916382</pmid><doi>10.1111/trf.12739</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0041-1132
ispartof Transfusion (Philadelphia, Pa.), 2014-12, Vol.54 (12), p.3080-3087
issn 0041-1132
1537-2995
language eng
recordid cdi_proquest_miscellaneous_1637567714
source Wiley-Blackwell Read & Publish Collection
subjects Adolescent
Adult
Aged
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Blood Platelets
Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis
Child
Female
Histocompatibility Testing
Humans
Male
Medical sciences
Middle Aged
Platelet Transfusion
Retrospective Studies
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
title Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T12%3A52%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utilization%20of%20cross-matched%20or%20HLA-matched%20platelets%20for%20patients%20refractory%20to%20platelet%20transfusion&rft.jtitle=Transfusion%20(Philadelphia,%20Pa.)&rft.au=Rioux-Mass%C3%A9,%20Benjamin&rft.date=2014-12&rft.volume=54&rft.issue=12&rft.spage=3080&rft.epage=3087&rft.pages=3080-3087&rft.issn=0041-1132&rft.eissn=1537-2995&rft.coden=TRANAT&rft_id=info:doi/10.1111/trf.12739&rft_dat=%3Cproquest_cross%3E1637567714%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5579-9e9deb986dea7449455fe4553d2dd16c287ab9c733e5f169d6dab0057a1b20d13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1635073274&rft_id=info:pmid/24916382&rfr_iscdi=true